Answers are grounded in this paper and cite their sources.
Meta-analysis shows nirmatrelvir/ritonavir significantly reduces death and hospitalization in immunocompetent patients, suggesting effective treatment options.
The high mutations of the Omicron variant of severe acute respiratory syndrome coronavirus 2 raised concerns regarding the efficacy of antivirals. This meta-analysis aimed to determine the impact of nirmatrelvir/ritonavir on the outcomes of immunocompetent patients with confirmed Omicron variant. Three reviewers systemically searched PubMed (Medline), Cochrane Library, and Embase databases up to June 9, 2025. Randomized clinical trials (RCTs) and observational studies with a control group were screened for eligibility to extract data. Studies that included only patients with immunosuppression, malignancy, or renal failure, severe disease, or assessed nirmatrelvir/ritonavir efficacy on variants other than Omicron were excluded. Forty-six observational studies, including 6,099,805 participants, were involved in the meta-analysis. Our findings revealed that nirmatrelvir/ritonavir significantly decreases death (risk ratio [RR] =0.31; 95% confidence interval [CI]: 0.23–0.40), disease progression (RR = 0.57; 95% CI: 0.42–0.71), hospitalization (RR = 0.45; 95% CI: 0.35–0.56), composite outcome of hospitalization and death (RR = 0.58; 95% CI: 0.44–0.71), ventilation (RR = 0.46; 95% CI: 0.19–0.72), and intensive care unit admission (RR = 0.56; 95% CI: 0.38–0.73) compared to the control group. However, no significant difference was shown across the two groups regarding hospitalization duration (mean difference = −2.34; 95% CI: −5.60–0.93). The current updated meta-analysis supported the efficacy of nirmatrelvir/ritonavir on the Omicron variant. However, further RCTs are recommended for accurate results.
No takes yet. Share an insight, caveat, or question.
Khani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: